2012

Regulation of p53 Stability and Apoptosis by a ROR Agonist

Yongjun Wang
The Scripps Research Institute

Laura A. Solt
The Scripps Research Institute

Douglas J. Kojetin
The Scripps Research Institute

Thomas P. Burris
The Scripps Research Institute, tburris@scripps.edu

Follow this and additional works at: https://digitalcommons.unl.edu/nutritionfacpub

Part of the Human and Clinical Nutrition Commons, Molecular, Genetic, and Biochemical Nutrition Commons, and the Other Nutrition Commons

Wang, Yongjun; Solt, Laura A.; Kojetin, Douglas J.; and Burris, Thomas P., "Regulation of p53 Stability and Apoptosis by a ROR Agonist" (2012). Nutrition and Health Sciences -- Faculty Publications. 173.
https://digitalcommons.unl.edu/nutritionfacpub/173

This Article is brought to you for free and open access by the Nutrition and Health Sciences, Department of at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Nutrition and Health Sciences -- Faculty Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Regulation of p53 Stability and Apoptosis by a ROR Agonist

Yongjun Wang, Laura A. Solt, Douglas J. Kojetin, Thomas P. Burris*  
The Scripps Research Institute, Jupiter, Florida, United States of America

Abstract

Activation of p53 function leading to cell-cycle arrest and/or apoptosis is a promising strategy for development of anti-cancer therapeutic agents. Here, we describe a novel mechanism for stabilization of p53 protein expression via activation of the orphan nuclear receptor, RORα. We demonstrate that treatment of cancer cells with a newly described synthetic ROR agonist, SR1078, leads to p53 stabilization and induction of apoptosis. These data suggest that synthetic ROR agonists may hold utility in the treatment of cancer.

Introduction

In approximately 50% of human cancers the p53 gene is mutated, but in the remaining half of cancers activation of p53 function is considered to be a valuable strategy for development of anti-cancer therapeutics. p53 plays a critical role in limiting cell proliferation and inducing apoptosis in response to cellular stress/damage and abnormal function of p53 is associated with cancers [1]. p53 function is tightly regulated by modulation of protein stability. Under most conditions, p53 protein is undetectable within the proximal promoter of the MDM2 and thus increases its stability [22]. In fact, induction of SOX4 expression is required for p53 stabilization in response to DNA damage [22]. Bioinformatic analysis of the RORα occupancy site revealed a putative ROR response element that was conserved between humans, mice and xenopus (Fig. 1A). We observed increased occupancy sites within the genome as we previously described [19]. We discovered RORα occupancy within the proximal promoter of the SOX4 gene (Fig. 1A), which we found particularly intriguing because of its role in the regulation of p53 stability and function [22]. The tumor suppressor p53 plays a critical role in limiting cell proliferation and inducing apoptosis in response to cellular stress/damage and abnormal function of p53 is associated with cancers [1]. SOX4 directly interacts with p53 limiting its ability to be ubiquitinated by MDM2 and thus increases its stability [22]. In fact, induction of SOX4 expression is required for p53 stabilization in response to DNA damage [22]. Bioinformatic analysis of the RORα occupancy site revealed a putative ROR response element that was conserved between humans, mice and xenopus (Fig. 1A). We confirmed occupancy of the SOX4 promoter by RORα using a ChIP assay as shown in Fig. 1B. The SOX4 promoter conveyed RORα-dependent regulation of a luciferase reporter gene in HEK293 cells as illustrated in Fig. 1C. This regulation was dependent on the RORE identified and shown in Fig. 1A since mutation of the RORE sequence rendered the construct unresponsive to RORα (Fig. 1D). Adenoviral overexpression of RORα in HepG2 cells resulted in an increase in SOX4 mRNA expression whereas knock-down of RORα expression reduced SOX4 mRNA expression in the same cell line (Fig. 1D). The limited effect on SOX4 mRNA after RORα knock-down may be due to compensatory actions of RORγ, which is known to act in concert with RORα in HepG2 cells [23]. Based on previous observations that altering SOX4 expression modulates p53

Results

A chromatin immunoprecipitation (ChiP) microarray screen was performed in the hepatocellular carcinoma cell line, HepG2, to identify RORα occupancy sites within the genome as we previously described [19]. We discovered RORα occupancy within the proximal promoter of the SOX4 gene (Fig. 1A), which was found particularly intriguing because of its role in the regulation of p53 stability and function [22]. The tumor suppressor p53 plays a critical role in limiting cell proliferation and inducing apoptosis in response to cellular stress/damage and abnormal function of p53 is associated with cancers [1]. SOX4 directly interacts with p53 limiting its ability to be ubiquitinated by MDM2 and thus increases its stability [22]. In fact, induction of SOX4 expression is required for p53 stabilization in response to DNA damage [22]. Bioinformatic analysis of the RORα occupancy site revealed a putative ROR response element that was conserved between humans, mice and xenopus (Fig. 1A). We confirmed occupancy of the SOX4 promoter by RORα using a ChIP assay as shown in Fig. 1B. The SOX4 promoter conveyed RORα-dependent regulation of a luciferase reporter gene in HEK293 cells as illustrated in Fig. 1C. This regulation was dependent on the RORE identified and shown in Fig. 1A since mutation of the RORE sequence rendered the construct unresponsive to RORα (Fig. 1D). Adenoviral overexpression of RORα in HepG2 cells resulted in an increase in SOX4 mRNA expression whereas knock-down of RORα expression reduced SOX4 mRNA expression in the same cell line (Fig. 1D). The limited effect on SOX4 mRNA after RORα knock-down may be due to compensatory actions of RORγ, which is known to act in concert with RORα in HepG2 cells [23]. Based on previous observations that altering SOX4 expression modulates p53
stability, we hypothesized that ROR\(\alpha\) expression may correlate with p53 protein stability [22]. Indeed, we observed that overexpression of ROR\(\alpha\) in HepG2 cells was associated with an increase in SOX4 expression leading to increased p53 protein levels (Fig. 1D). Consistent with this observation, decreasing ROR\(\alpha\) expression in these cells leads to decreased p53 protein levels (Fig. 1E). We directly measured the stability of p53 under conditions where ROR\(\alpha\) was overexpressed by treating cells with cychoheximide and noted that overexpression of ROR\(\alpha\) clearly stabilized p53 expression (Fig. 1F). Additionally, overexpression of ROR\(\alpha\) led to increased expression of p53 target genes that play a key role in cell cycle arrest \(p21\) and apoptosis \(PUMA\) (Fig. 2A) [1]. Knock-down of p53 suppressed the ability of ROR\(\alpha\) overexpression to increase the expression of these genes (Fig. 2A lower panels). Further, analysis of HepG2 cells overexpressing ROR\(\alpha\) revealed that the number of cells in sub-G1 increased substantially over control cells (34% vs 8%) while cells in S and G2/M phase were also substantially reduced consistent with induction of apoptosis (Figs. 2B & 2C). These data are consistent with the observed increase in p53 stability and increase in \(p21\) and \(PUMA\) expression noted in Fig. 2B. Furthermore, the increase in sub-G1 cells induced by overexpression of ROR\(\alpha\) was blocked when p53 expression was knocked down demonstrating that ROR\(\alpha\) induction of apoptosis is p53-dependent (Fig. 2D). MCF-7 breast cancer cells show similar results when ROR\(\alpha\) is overexpressed; a significant increase in sub-G1 cells relative to control cells (15.5% vs 4.5%) (Fig. 2E).

Based on our results where overexpression of ROR\(\alpha\) leads to increased p53 protein stability, we examined the potential of a ROR\(\alpha\) agonist we recently identified to increase p53 stability. We recently characterized several synthetic ROR ligands including the first synthetic, selective ROR ligand, SR1078 (Fig. 3A) [24,25,26]. SR1078 functions as an agonist by activating ROR\(\alpha\) leading to an increase in transcription of ROR\(\alpha\) target genes [24]. Consistent with this activity, we noted that SR1078 induced the expression of SOX4 mRNA in HepG2 cells as well as a well-characterized ROR\(\alpha\) target gene, REV-ER\(\beta\) (Fig. 3B). We observe that SR1078 treatment also results in an increase in p53 protein levels (Fig. 3C) similar to the results we observed with overexpression of ROR\(\alpha\). SR1078 treatment also led to a significant increase in the expression of p53 target genes \(p21\) and \(PUMA\) (Fig. 3D). Knock-down of p53 suppressed the ability of SR1078 to increase the expression of these genes (Fig. 3D lower panels). Consistent with the increase in p53 protein levels as well as the increase in the expression of p53 target genes, we found that SR1078 treatment led to increased apoptosis as indicated by the increase in HepG2 cells in sub-G1 (0.9% control vs. 9.4% SR1078) (Fig. 3E). The increase in apoptosis induced by SR1078 was both ROR\(\alpha\)- and p53-dependent since siRNA-mediated knock down of either of these genes suppressed the ability of SR1078 to increase cells in sub-G1 (Figs. 3F &3G).

**Discussion**

The tumor suppressor protein p53 plays an essential role in regulation of key cellular processes including DNA repair, cell cycle, and apoptosis. In approximately half of all human cancers the p53 gene is deleted or mutated [1]. In many cancers with wild type p53, the activity of the tumor suppressor is inhibited by various effectors. One clear example of this is found in tumors where MDM2 is overexpressed due to an amplification of a chromosome segment that includes MDM2 [27]. This leads to abnormal degradation of p53 and thus a similar phenotype to tumors with a mutant or deleted p53 gene. Inhibition of abnormal degradation of p53 is a logical pharmacological target and, in fact, several small molecule inhibitors of the MDM2-p53 interaction including nutlin-3, RITA, spirinoxidoles and quilinols are being investigated as anti-cancer agents due to their abilities to increase cellular p53 protein levels through inhibition of MDM2-directed proteosomal degradation of p53 [28].

Our data suggests that a small molecule synthetic ROR\(\alpha\) agonist can increase p53 protein stability leading to increased p53 function and subsequent apoptosis. MDM2 inhibitors have been the focus of significant efforts to develop anti-cancer agents that function via activation of p53 activity. Here, we demonstrate that ROR\(\alpha\) agonists may also be useful for activation of p53 activity and thus represent a novel target for development of anti-cancer therapeutics. Most nuclear receptors that have identified ligands are well-characterized targets for drugs used in the clinic and the nature of the nuclear receptor ligand binding domain typically allows for optimization of small molecule ligands for drug development. Thus, ROR\(\alpha\) clearly represents a unique target for stabilization of p53 that is quite distinct from the challenging effort to inhibit a protein-protein interaction such as the MDM2-p53 interaction. While this manuscript was under revision, Kim et al. also described a role for p53 in regulation of p53 stability and function [29]. Although they show also that ROR\(\alpha\) regulates p53 stability they demonstrate a distinct mechanism from that proposed in this manuscript for increasing p53 stability involving the enhancement of p53-HAUSP interaction [29]. Kim et al indicate that they could not rule out additional non-HAUSP mechanism for regulation of p53 stability by ROR\(\alpha\) [29], which is consistent with our observation that ROR\(\alpha\) directly regulates the expression of SOX4, a critical gene involved in MDM2-dependent regulation of p53 stability.

**Methods**

Plasmids and viruses

The SOX4 promoter (-1121 to +90) was amplified from genomic DNA of HepG2 cells (ATCC, Manassas, VA) and cloned into pTAL-Luc luciferase report vector (Clontech, CA) to make the pTAL-SOX4 reporter construct. PGL4.73 reporter was from Promega (Madison, WI). pTrex-ROR\(\alpha\) and pTrex-ROR\(\gamma\) were from Phenex Pharmaceuticals AG. ROR\(\alpha\) was tagged with FLAG and subcloned into pAd/CMV/V5-DEST vector through Gateway\TM technique (Invitrogen). The adenovirus with FLAG-ROR\(\alpha\) was produced according to the manufacturer’s instructions.

Site-directed Mutagenesis

The SOX4 promoter mutant constructed by site directed mutagenesis as previously described [25,30]. The RORE (−178 to −165) was mutated from GGAATGAGGTCAG to GGAAT-GAGGGGG. The mutant primers targeting ROR binding site are: GCTCTGTAAATGGAAATGAGGGGATTTGGAAGG-TTCTC (forward) and GAGAAAGCTCAATCCCCCTACA-TTCGAATTGAGGAGC (reverse). The mutant primers were used to amplify mutant plasmid from pTAL-SOX4 reporter using PfuUltra HF DNA polymerase. The PCR product were treated with Dpn I to select for mutation-containing synthesized DNA and then transformed into XL1-Blue supercompetent cells. Positive clones were picked up and grown overnight in LB media. The plasmid were isolated using QIAprep Spin Miniprep Kit (Qiagen).

The mutant construct was verified by sequencing.

Cell culture and luciferase assay

HEK293 cells (ATCC) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine...
serum (Invitrogen, Carlsbad, CA) at 37°C under 5% CO2. 24h prior to transfection, HEK293 cells were plated in 96-well plates at a density of 15 × 10^3 cells/well. Transfections were performed using Lipofectamine™ 2000 (Invitrogen). Each well was transfected with 20 ng pGL4.73, 50 ng ROR and 100 ng pTAL-Luc or mutant. Eight hours post-transfection, the cells were treated with vehicle or ligands. Twenty-four hours post-treatment, the luciferase activity was measured using the Dual-Glo™ luciferase assay system (Promega). The value from experimental reporter was normalized to control reporter. The values indicated represent the means ± S.E. from four independently transfected wells. The experiments were repeated at least three times.

**Overexpression of RORα and siRNA Knockdown**

The HepG2 cells (ATCC) were maintained in MEM supplemented with 10% fetal bovine serum at 37°C under 5% CO2. HepG2 cells were plated in 6-well plate one day before infection. The cells were infected with adenovirus for 24 hours and then

---

**Figure 1. Identification of a RORE in the SOX4 promoter.**

A) Schematic representing the SOX4 gene. The single exon gene is shown in the diagram the untranslated regions are also shown. The area where significant RORα occupancy was detected in the ChIP-microarray screen is indicated above the gene. The putative RORα is shown below the gene structure and alignment illustrates absolute conservation between xenopus, mouse and human sequences. The RORE is indicated by the underlined sequence. Alignment of the putative SOX4 RORE with the prototypic RORE from the prototypic ROR target gene, BMAL1. Right Panel: Screen shot from genome browser indicating regions generating signal from the ChIP/chip study on both SOX4 and the positive control ARNTL (BMAL1). B) Chromatin immunoprecipitation assessing the occupancy of RORα at the SOX4 promoter. IgG was used as a negative control and RNA polII was used as a positive control. C) Cotransfection assay where a luciferase reporter under the direction of the SOX4 promoter was transfected into HEK 293 cells along with a vector directing the expression of RORα. Inclusion of RORα results in stimulation of luciferase expression. The second panel demonstrates that when the RORE is mutated in the SOX4 promoter, which inhibits the ability of RORα to bind, RORα no longer has the ability to activate transcription of this reporter. WT, indicates wild type and MT, indicates mutant. Empty expression vector was included in the control wells. D) Adenoviral overexpression of RORα in HepG2 cells results in stimulation of SOX4 mRNA expression relative to the LacZ adenovirus control. Suppression of expression of RORα using siRNA results in a reduction of SOX4 mRNA. * indicates p<0.05. E) Western blot illustrating that overexpression of RORα results in increased p53 protein while suppression of RORα expression results in decreased p53 protein expression. F) Analysis of the effect of RORα overexpression on the half-life of p53. HEK293 cells overexpressing either LacZ (control) or RORα were treated with cycloheximide for various amounts of time (0, 10, 60, 90 min) and p53 protein was assessed by western analysis and normalized to tubulin expression. Densitometry was used to assess expression and was signal was normalized to tubulin and the normalized relative (to time 0) expression is indicated below the blots. p53 displayed a half-life of 22 ± 6 min (mean ± S.E.) in the absence of RORα and a half-life >90 min with RORα overexpressed.

doi:10.1371/journal.pone.0034921.g001
switched to regular growth media. Twenty-four hours later, the cells were harvested to isolate total RNA. For knockdown assay, the control siRNA, human RORα siRNA, and human p53 siRNA (Thermo Scientific) were transfected with Lipofectamine™ RNAiMAX (Invitrogen) by using reverse transfection. After 24 hours, cells were harvested to perform quantitative PCR assay or western blot.

cDNA synthesis and quantitative PCR

Total RNA extraction and cDNA synthesis were performed as described before. The quantitative PCR was performed using ABI Prism 7900 HT detection system (Applied Biosystems, Foster City, CA). The primers for quantitative PCR are: human RORα, AAACAAGCGCGGAGGAGTGA (forward) and TGGCAAACCTCCACCACATAC (reverse); human SOX4, GTGGTACGGGGGCAGTGTCA (forward) and AACACCATCACGATTCCGAT (reverse); human P21, TTAGCAGCGGAAGT (forward) and CAACTACTCCCAGCTAGTT (reverse); human PUMA, CTGTGCTCTGCCCGTGACCG (forward) and CTGGGGCGGCTTCAGCCAAA (reverse); human BAX, GAGGATGATTGCCGCCGTGG (forward) and ACCGGCCCCAGTTGAAGTT (reverse); human CYPB, GCAAATTCCATCGTGTAATCAAG (forward) and CGTAGATGCCGTCCCTCTCG (reverse). The expression of target gene was normalized to housekeeping gene CYPB.

Western Analysis

HepG2 cells were washed once with phosphate-buffered saline and then incubated for 10 min at 4°C in 100 µl of TNT lysis buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, and 1% Triton X-100) and a complete mini protease inhibitor mixture (Roche Applied Science). Samples were then scraped and harvested into 1.5-ml microcentrifuge tubes, vortexed for 30 s, and then centrifuged (425 g for 10 min). Protein levels in the supernatants

Figure 2. RORα regulates p53 function. A) Overexpression of RORα in HepG2 cells results in increased expression of p53 target genes including p21, BAX, and PUMA. In control cells where the RORα adenovirus was not included, a control LacZ adenovirus was used. *, indicates p<0.05. Experiments shown in the lower panels were performed identical to the upper panels with the exception of inclusion of siRNA treatments as indicated. B) Cell cycle analysis of control HepG2 cells infected with LacZ adenovirus (top) or RORα adenovirus (bottom). C) Analysis of the number of cells in various stages of the cell cycle in control or RORα overexpressing HepG2 cells. D) Cell cycle analysis of HepG2 cells overexpression RORα (adenovirus treatment) after treatment with either control siRNA or p53 siRNA. E) Analysis of the number of MCF-7 breast cancer cells in sub-G1 infected with control adenovirus (LacZ) or RORα adenovirus. *, indicates p<0.05.

doi:10.1371/journal.pone.0034921.g002
were determined using a Coomassie protein assay kit (Bio-Rad), and 20 μg of protein from each sample was separated by SDS-PAGE (BioRad - 10%) and then transferred to a polyvinylidene difluoride membrane (Millipore, Milford, MA) and immunoblotted with primary antibodies: RORα (BioLegend), TP53 (Cell Signaling) or α-tubulin (Sigma) and horseradish peroxidase-conjugated secondary antibodies (Jackson Immunoresearch). Detection of the bound antibody by enhanced chemiluminescence was performed according to the manufacturer’s instructions (Santa Cruz). For p53 half-life experiments, 10 μM cyclohexamide was added to the cells for 30, 60, or 90 minutes prior to harvesting the HepG2 cells for western analysis.

FACS analysis
HepG2 cells and MCF7 cells (ATCC) were plated in 24-well plates the day before infection. The cells were infected with adenovirus 24 hours later. On the day of analysis, cells were harvested, washed, and fixed with 70% ethanol at 220°C. Fixed samples were washed with PBS twice and resuspended in propidium iodide staining solution for 30 min. Stained cells were analyzed on a FACScan flow cytometer (Beckton Dickinson).

ChIP/chip screening
HepG2 cells were infected with adenovirus for 24 hours and then switched to regular growth media for another 24 h. The cells were harvested and sent to Genpathway for ChIP/chip assay as previously described [31,32,33]. The RORα ChIP/chip experiment has been previously described [19].

Statistical Analysis
The Student’s t test was used to test for significant differences between groups.

Author Contributions
Conceived and designed the experiments: TB LS YW. Performed the experiments: LS YW. Analyzed the data: TB LS YW DK. Contributed reagents/materials/analysis tools: TB LS YW DK. Wrote the paper: TB.
References

1. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307–310.
2. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, et al. (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. Journal of the National Cancer Institute 93: 1563–1568.
3. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, et al. (2003) Night-shift work and risk of colorectal cancer in the Nurses’ Health Study. Journal of the National Cancer Institute 95: 825–830.
4. Megdal SP, Krouenke CH, Laden F, Pukkala E, Schernhammer ES (2005) Night work and breast cancer risk: A systematic review and meta-analysis. European Journal of Cancer 41: 2023–2032.
5. Hansen J (2001) Increased breast cancer risk among women who work predominantly at night. Epidemiology 12: 74–77.
6. Sato TK, Panda S, Miraglia LJ, Reyes TM, Rudic RD, et al. (2004) A functional clock. Neuron 43: 527–537.
7. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, et al. (2005) Deregulated expression of the mammalian core-clock Bmal1. Nature Structural & Molecular Biology 12: 441–448.
8. Kuo SJ, Chen ST, Yeh KT, Hou MF, Li TC, et al. (2008) Disturbance of the core mammalian clock component, NPAS2, as a REV-ERBalpha/RORalpha target gene. Journal of Biological Chemistry 283: 35386–35392.
9. Liu YM, Chang JH, Yeh KT, Yang MY, Li TC, et al. (2000) Disturbance of Circadian Gene Expression in Hepatocellular Carcinoma. Molecular Carcinogenesis 47: 925–933.
10. Lin YM, Chang JH, Yeh KT, Yang MY, Li TC, et al. (2008) Disturbance of Circadian Gene Expression in Hepatocellular Carcinoma. Molecular Carcinogenesis 47: 925–933.
11. van den Heiligenberg S, Depres-Brummer P, Barbason H, Claustrat B, Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, et al. (2004) Effects of constant light exposure on circadian gene expression in breast cancer. Virchows Archiv 454: 3405–3407.
12. Filipski E, King VM, Li XM, Granda TG, Mormont MC, et al. (2002) Host circadian clock as a control point in tumor progression. Journal of the National Cancer Institute 94: 690–697.
13. Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, et al. (2004) Effects of chronic jet lag on tumor progression in mice. Cancer Research 64: 7879–7885.
14. Shah PN, Mhatre MC, Kothari LS (1984) EFFECT OF MELATONIN ON CIRCADIAN TRANSCRIPTION OF THE MAMMALIAN CORE-CLOCK BMAL1. Nature Structural & Molecular Biology 12: 441–448.
15. Wang Y, Kumar N, Soh LA, Richardson TJ, Helferling LM, et al. (2010) Identification of RORalpha and RORgamma activity by 7-oxygenated steroid ligands. Journal of Biological Chemistry 285: 5013–5025.
16. Wang Y, Kumar N, Nuhant P, Cameron MD, Istrate MA, et al. (2010) Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors RORA and RORB. ACS Chemical Biology, pp. 1029–1034.
17. Wang Y, Kumar N, Nuhant P, Cameron MD, Istrate MA, et al. (2010) Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors RORA and RORB. ACS Chemical Biology, pp. 1029–1034.
18. Wang Y, McMurray BS, Kuhn R, Smith DJ (2006) RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene 25: 2901–2908.
19. Wang Y, Vazquez-Solar M, Vazquez M, Vazquez F, Montesinos T, et al. (2006) Identification of SR3335 (ML-176): A Synthetic ROR alpha Selective Inverse Agonist. ACS Chemical Biology 6: 218–222.
20. Wang Y, Koejiri RJ, Mohr MD, Simpson CA, Fewell NA, et al. (2006) Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors RORA and RORB. ACS Chemical Biology, pp. 1029–1034.
21. Wang YJ, Rogers PM, Stayrook KR, Su C, Varga G, et al. (2008) The Selective RORalpha Agonist SR1078 Induces Apoptosis and Inhibits Tumor Growth in Tumor Xenograft Models. Molecular Pharmacology 74: 1716–1721.
22. Wang YJ, Kumar N, Nuhant P, Cameron MD, Istrate MA, et al. (2010) Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors RORA and RORB. ACS Chemical Biology, pp. 1029–1034.
23. Wang YJ, Kumar N, Soh LA, Richardson TJ, Helferling LM, et al. (2010) Identification of RORalpha and RORgamma activity by 7-oxygenated steroid ligands. Journal of Biological Chemistry 285: 5013–5025.
24. Kim H, Lee JL, Lee G, Bhin J, Oh SK, et al. (2011) DNA damage-induced RORalpha is crucial for p53 stabilization and increased apoptosis. Molecular Cell 44: 797–810.
25. Philipps E, Delaunay F, King VM, Wu MW, Claustrat B, et al. (2004) Effects of constant light exposure on circadian gene expression in breast cancer. Virchows Archiv 454: 3405–3407.
26. Filipski E, King VM, Li XM, Granda TG, Mormont MC, et al. (2002) Host circadian clock as a control point in tumor progression. Journal of the National Cancer Institute 94: 690–697.
27. Lin YM, Chang JH, Yeh KT, Yang MY, Li TC, et al. (2000) Disturbance of Circadian Gene Expression in Hepatocellular Carcinoma. Molecular Carcinogenesis 47: 925–933.
28. van den Heiligenberg S, Depres-Brummer P, Barbason H, Claustrat B, Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, et al. (2004) Effects of chronic jet lag on tumor progression in mice. Cancer Research 64: 7879–7885.
29. Shah PN, Mhatre MC, Kothari LS (1984) EFFECT OF MELATONIN ON CIRCADIAN TRANSCRIPTION OF THE MAMMALIAN CORE-CLOCK BMAL1. Nature Structural & Molecular Biology 12: 441–448.
30. Wang Y, Kumar N, Nuhant P, Cameron MD, Istrate MA, et al. (2010) Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors RORA and RORB. ACS Chemical Biology, pp. 1029–1034.
31. Wang YJ, Rogers PM, Stayrook KR, Su C, Varga G, et al. (2008) The Selective RORalpha Agonist SR1078 Induces Apoptosis and Inhibits Tumor Growth in Tumor Xenograft Models. Molecular Pharmacology 74: 1716–1721.
32. Wang YJ, Rogers PM, Stayrook KR, Su C, Varga G, et al. (2008) The Selective RORalpha Agonist SR1078 Induces Apoptosis and Inhibits Tumor Growth in Tumor Xenograft Models. Molecular Pharmacology 74: 1716–1721.
33. Wang YJ, Kumar N, Soh LA, Richardson TJ, Helferling LM, et al. (2010) Identification of RORalpha and RORgamma activity by 7-oxygenated steroid ligands. Journal of Biological Chemistry 285: 5013–5025.
34. Kim H, Lee JL, Lee G, Bhin J, Oh SK, et al. (2011) DNA damage-induced RORalpha is crucial for p53 stabilization and increased apoptosis. Molecular Cell 44: 797–810.
35. Wang YJ, Soh LA, Burris TP (2010) Regulation of FGF21 Expression and Secretion by Retinoic Acid Receptor-related Orphan Receptor alpha. Journal of Biological Chemistry 285: 15668–15673.
36. Wang YJ, Rogers PM, Stayrook KR, Su C, Varga G, et al. (2008) The Selective Alzheimer’s Disease Indicator-1 Gene (Seladin-1/DHCR24) Is a Liver X Receptor Target Gene. Molecular Pharmacology 74: 1716–1721.
37. Wang YJ, Rogers PM, Stayrook KR, Su C, Varga G, et al. (2008) The Selective Alzheimer’s Disease Indicator-1 Gene (Seladin-1/DHCR24) Is a Liver X Receptor Target Gene. Molecular Pharmacology 74: 1716–1721.
38. Wang YJ, Rogers PM, Stayrook KR, Su C, Varga G, et al. (2008) The Selective Alzheimer’s Disease Indicator-1 Gene (Seladin-1/DHCR24) Is a Liver X Receptor Target Gene. Molecular Pharmacology 74: 1716–1721.
39. Wang YJ, Rogers PM, Stayrook KR, Su C, Varga G, et al. (2008) The Selective Alzheimer’s Disease Indicator-1 Gene (Seladin-1/DHCR24) Is a Liver X Receptor Target Gene. Molecular Pharmacology 74: 1716–1721.